Browse > Article

Well-Managed Myelodysplastic Syndrome Patients Treated with Traditional Korean Medicine; Report of Two Cases  

Kim, Jun-young (Internal Medicine of Immunology, Dae-Jeon Oriental Hospital of Dae-Jeon University)
Joung, Jin-yong (Internal Medicine of Immunology, Dae-Jeon Oriental Hospital of Dae-Jeon University)
Son, Chang-gue (Internal Medicine of Immunology, Dae-Jeon Oriental Hospital of Dae-Jeon University)
Cho, Jung-hyo (Internal Medicine of Immunology, Dae-Jeon Oriental Hospital of Dae-Jeon University)
Publication Information
The Journal of Internal Korean Medicine / v.37, no.3, 2016 , pp. 539-547 More about this Journal
Abstract
Myelodysplastic syndrome (MDS) is a typical myeloid malignancy characterized by cell dysplasia in bone marrow. Currently, there is no therapeutic treatment for MDS. The only available therapies either relieve symptoms or prevent the development of acute myeloid leukemia (AML). This study aimed to report the effects of traditional Korean medicine (TKM) on MDS by presenting two case reports. The patient in Case 1 was diagnosed with primary MDS and regularly received acupuncture treatments and herbal medicine. In Case 2, a patient with ovarian cancer was diagnosed with secondary MDS, which resulted from an adverse reaction to chemotherapy. This patient took herbal medicine for four years and was hospitalized three times. In order to have their condition evaluated, both patients underwent regular blood tests. The patient in Case 1, who showed blood transfusion dependency, received only two blood transfusions after TKM treatment, and the person’s health condition was stable as of January 2016 without any signs of AML development. The patient in Case 2 also has stable health condition. TKM treatment effectively treated their MDS symptoms and improved their general health conditions without any adverse effects. It also prevented the rapid development of AML and maximized the effects of conservative therapy.
Keywords
Myelodysplastic syndrome; traditional Korean medicine; acupuncture; herbal medicine; case report;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Disperati P, Ichim CV, Tkachuk D, Chun K, Schuh AC, Wells RA. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res 2006;30(2):233-9.   DOI
2 Cazzola M, Malcovati L. Myelodysplastic syndromescoping with ineffective hematopoiesis. N Engl J Med 2005;352(6):536-8.   DOI
3 Park EH, Lee HW, Won YJ, Ju, HY, Oh CM, Ingabire C, et al. Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. Blood Res 2015;50(4):204-17.   DOI
4 Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82(2):358-67.   DOI
5 Tricot GJ. Prognostic factors in the myelodysplastic syndromes. Leuk Res 1992;16(1):109-15.   DOI
6 Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45-52.   DOI
7 Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014;12(3):172-8.
8 García-Delgado R, de Miguel D, Bailén A, González JR, Bargay J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res 2014;38(7):744-50.   DOI
9 Kim JD. A case of myelodysplastic syndrome. J Int Korean Med 1999;20(1):274-9.
10 Kim BS. Asian image-mathematics system from the viewpoint of three category. Korean J Oriental Physiology & Pathology 2007;21(5):1065-71.
11 Song HW. Literature review on practical use of Sibjeondaebo-tang. J Herb Formula Sci 1996;4(1):153-72.
12 Lee MH. Experimental studies on the hematopoietic effects of Cervi pantotrichum Cornu. Graduate school of Daejeon university 2001.
13 Lee NH, Yoon DH, Yoo HS, Cho JH, Son CG, Lee YW, et al. Change of serum vegf, bfgf levels and platelet counts in 100 cancer patients treated with hand-am-dan. J Int Korean Med 2005;26(4):753-60.
14 Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100(21):1542-51.   DOI
15 Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006;91(12):1588-90.
16 Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013; 13 Suppl 2:S295-9.   DOI
17 Klepin HD, Rao AV, Pardee TS. Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults. J Clin Oncol 2014;32(24):2541-52.   DOI
18 Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25(23):3503-10.   DOI